je.st
news
Tag: drug
Illinois Medicaid restricts use of hepatitis drug
2014-07-31 06:02:16| Biotech - Topix.net
After spending an estimated $16 million this fiscal year on Sovaldi, which holds promise for a cure for the liver-damaging disease, the state agency headed by Julie Hamos approved the restrictions July 10. The rules limit the drug to sicker patients and bar it for anyone with a history of drug or alcohol abuse within the past year.
Tags: drug
illinois
hepatitis
medicaid
Sanofi, Regeneron drug cuts cholesterol in nine late-stage trials
2014-07-30 16:33:34| Biotech - Topix.net
A new drug being developed by French drugmaker Sanofi and U.S. partner Regeneron cut "bad" LDL cholesterol more than placebo and existing treatments in nine late-stage clinical trials, the companies said on Wednesday.
Tags: drug
cuts
trials
cholesterol
Exploring The Challenges In Drug Delivering System For Efficient Solutions
2014-07-30 11:04:24| drugdiscoveryonline Home Page
Although OMICS Group focused in the year 2011-2014 on exploring the novel research in the field of Pharmaceutics and NDDS, it spared the year 2015 to share international experiences with the world leaders from Pharmaceutical and Bio Pharmaceutical Research diverting a major section of research to focus on formulating a variety of poorly soluble and highly unstable substances, reporting it to be the significant arena in pharmaceutical research
Tags: system
solutions
drug
efficient
Regulus Receives Orphan Drug Designation For RG-012, A microRNA Therapeutic For The Treatment Of Alport Syndrome
2014-07-30 10:28:24| drugdiscoveryonline Home Page
Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that the U.S. Food & Drug Administration (FDA) has granted orphan drug designation to RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21"), as a therapeutic for the treatment of Alport syndrome, a life-threatening genetic kidney disease with no approved therapy
Tags: of
treatment
drug
receives
Lpath Reports Interim Data From Phase 2a Study For Anti-Cancer Drug, ASONEP
2014-07-30 10:19:09| drugdiscoveryonline Home Page
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, reported interim results in a Phase 2a single-arm, open-label trial where ASONEP™ is being investigated as a treatment for metastatic renal cell carcinoma (RCC) in patients that have failed at least one therapy involving a VEGF inhibitor (e.g., Sutent®/ sunitinib maleate) and no more than one mTOR inhibitor (e.g., Afinitor®/everolimus), with a maximum of three failed treatments in all
Sites : [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] [150] [151] [152] [153] [154] [155] next »